 |
 |
 |
August, 2010
25th Annual Report 2009-10 |
| |
|
|
May 31, 2010
Audited Financial Result For March 2010 Qtr |
| |
|
|
January 27, 2010
Unaudited Financial Result For December 2009 Qtr |
| |
 |
|
| |
 |
 |
 |
|
| Click here to know more about your health and health care info... |
|
|
|
 |
|
 |
|
| |
|
| |
 |
 |
 |
| |
| Alaxin Plus Tablets |
| Pharmacology |
| Dihydroartemisinin is powerful plasmodicide of malaria parasite agamete which quickly controls symptoms. Highly effective against all forms of malaria including multi-drug resistant malaria. It has high safety and low toxicity. Reproduction toxicity increase fetal absorption during pregnancy in mice. No mutation effects observed. Pyrimethamine and sulfadoxine act sequentially in the bacterial path way of folic acid synthesis to inhibit the enzyme dihydrofolate reductase, which converts dihydrofolate to tetrahydrofolate. Sulfadoxine and pyrimethamine do not affect mammalian cell since these cells are unable to synthesize folic acid themself and require intact folic acid. |
| Pharmacokinetics |
Oral administration of Dihydroartemisinin. Absorption is rapid and complete, and the active agent takes effect promptly. Human pharmacokinetic parameters : oral dosage 2 mg/kg. T max = 0.71 µg/ml, T½ = 1.57 h. Special feature : absorption rapidly, distribution extensively, excretion and metabolism quickly.
Pyrimethamine is well absorbed after oral administration to healthy volunteers, although the absolute bioavailability in man is not known. In monkeys the bioavailability of oral pyrimethamine was virtually complete. The mean absorption rate constant in man was 3.03 h -1 (t½ absorption approximately 15 min.) Plasma concentration peak at 2-6 hours in healthy human subjects and the maximum plasma concentration following a single 25 mg dose in 234+21 g.l -1. The mean elimination half life in several studies in 85 hours with a reported range of 35-175 hours. Total body clearance is 25+4 ml.h 1 kg-1. Pyrimethamine is lipid soluble and has a high apparent volume of distribution of 2.9 + 0.51kg.
Unlike many other long acting drugs sulfadoxine is rapidly absorbed. Oral administration of 2 g sulfadoxine gives peak serum levels of 180 to 200 ml.r1 within 2-4 hours. The serum has half-life of 150-200 hours. A week after single oral dose 1-2 g. there is still more than 80 mg.r1, sufficient to be therapeutically active. On prolonged treatment with 0.5 g. sulfadoxine a week the plasma concentration reaches a steady-state level of 98.4 mg.1-1 after about seven weeks. The sulphonamide and its metabolites are bound to plasma proteins to the extent of about 94%. |
| Side Effects |
| No side effects have been reported on clinical dosage. However, very few cases of temporary reticulocyte substance have been noted. |
| Contraindications |
Known sulfonamide hypersensitivity : There is usually cross allergy between all the sulfonamide.
There is no satisfactory test for sulfonamide allergy.
Severe renal or hepatic impairment : Crystalluria may occur in hypoproteinaemic patients, causing further renal damage.
Hepatocellular, jaundice, due to hypersensitivity may exacerbate hepatic impairment. |
| Dosage and Adminstration : Standard Dosage - Adults |
| Non-immune Patients |
Semi-immune Patients Weighing |
| A single dose of 3 Tabs |
60 kg or less : Single dose of 2 tabs
More than 60 kg : Single dose of 3 tabs |
|
| Adverse Reaction |
Known sulfonamide hypersensitivity : There is usually cross allergy between all the sulfonamide. There is no satisfactory test for sulfonamide allergy.
Severe renal or hepatic impairment : Crystalluria may occur in hypoproteinaemic patients, causing further renal damage.
Hepatocellualar jaundice, due to hypersensitivity may exacerbate hepatic impairment.
Blood dyscrasias : Sulfonamide may cause acute agranulocytosis and, more rarely aplastic anaemia, megaloblastic anaemia and thrombocytopenia.
Premature and new born infants : Sulfonamide compete with bilirubin for albumin binding site and precipiate kermicterus. |
| Pregnancy |
| Falcipar has not been recommended in early pregnancy because of the possiblity to teratogenicity. It is not recommended for use in the last two weeks of pregnancy because of the immaturity of neonatal hepatic enzyme system and possibility of kernicterus. However, sulfadoxine has been used safely in pregnancy. |
| Presentation |
| 3 Tabs strip. 10 x 3 tablets in a box. |
|
|
| |
|
|
Back 